Enhancement of the intestinal absorption of peptides and non-peptides

Journal of Controlled Release

Volumn 41, Issue 1-2, 1996, Pages 19-31

  Aungst, Bruce J ^a   Saitoh, Hiroshi ^a,b   Burcham, Deborah L ^a   Huang, Shiew Mei ^a   Mousa, Shaker A ^a   Hussain, Munir A ^a  

^a DUPONT COMPANY   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Bioavailability; Enhancement; Intestinal permeation; Oral absorption

Indexed keywords

4 PENTAFLUOROETHYL 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ACYLCARNITINE; ACYLGLYCEROL; ANGIOTENSIN II ANTAGONIST; BILE SALT; CHITOSAN; CHOLIC ACID; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; DECANOATE SODIUM; DEOXYCHOLATE SODIUM; DOCUSATE SODIUM; DODECYL SULFATE SODIUM; EXCIPIENT; FATTY ACID; FIBRINOGEN RECEPTOR ANTAGONIST; OLEIC ACID; PALMITOYLCARNITINE; PENETRATION ENHANCING AGENT; PEPTIDE; PHOSPHOLIPID; POLYCARBOPHIL; POLYOXYETHYLENE ALKYL ETHER; POLYSORBATE; SALICYLATE SODIUM; SURFACTANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONFERENCE PAPER; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; HUMAN; INTESTINE ABSORPTION; MEMBRANE PERMEABILITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REPRODUCIBILITY;

EID: 0030222346     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01353-3     Document Type: Conference Paper

References (55)

1. [1] S. Lundin and P. Artursson, Absorption of vasopressin analogue, 1-deamino-8-D-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell line, CaCO-2, Int. J. Pharm. 64 (1990) 181-186.
2. [2] B.J. Aungst, J.A. Blake and M.A. Hussain, An in vitro evaluation of metabolism and poor membrane permeation impeding intestinal absorption of leucine enkephalin, and methods to increase absorption, J. Pharmacol. Exp. Ther. 259 (1991) 139-145.
3. [3] E.J. van Hoogdalem, A.G. de Boer and D.D. Breimer, Intestinal drug absorption enhancement: an overview, Pharm. Ther. 44 (1989) 407-443.
4. [4] E.S. Swenson and W.J. Curatolo, Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity, Adv. Drug Del. Rev. 8 (1992) 39-92.
5. [5] B.J. Aungst, Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism, J. Pharm. Sci. 82 (1993) 979-987.
6. [6] K. Kakemi, H. Sezaki, R. Konishi, T. Kimura and M. Murakami, Effect of bile salts on the gastrointestinal absorption of drugs. I., Chem. Pharm. Bull. 18 (1970) 275-280.
7. [7] E. Ziv, A. Eldor, Y. Kleinman, H. Bar-On and M. Kidron, Bile salts facilitate the absorption of heparin from the intestine, Biochem. Pharmacol. 32 (1983) 773-776.
8. [8] M. Kidron, H. Bar-On, E.M. Berry and E. Ziv, The absorption of insulin from various regions of the rat intestine, Life Sci. 31 (1982) 2837-2841.
9. [9] S. Feldman and M. Gibaldi, Physiologic surface-active agents and drug absorption I: effect of sodium taurodeoxycholate on salicylate transfer across the everted rat intestine, J. Pharm. Sci. 58 (1969) 425-428.
10. [10] R.W. Freel, M. Hatch, D.L. Earnest and A.M. Goldner, Role of tight-junctional pathways in bile salt-induced increases in colonic permeability, Am. J. Physiol. 245 (1983) G816-G823.
11. [11] S. Teichberg, E. McGarvey, M.A. Bayne and F. Lifshitz, Altered jejunal macromolecular barrier induced by α-dihydroxy deconjugated bile salts, Am. J. Physiol. 245 (1983) G122-G132.
12. [12] J.J. Rafter, V.W.S. Eng, R. Furrer, A. Medline and W.R. Bruce, Effects of calcium and pH on the mucosal damage produced by deoxycholic acid in the rat colon, Gut 27 (1986) 1320-1329.
13. [13] E. Miyamoto, A. Tsuji and T. Yamana, Effects of surfactants on the GI absorption of β-lactam antibiotics in rats, J. Pharm. Sci. 72 (1983) 651-654.
14. [14] M. Sekine, K. Sasahara, K. Hasegawa, R. Okada and S. Awazu, Improvement of bioavailability of poorly absorbed drugs. V. Effect of surfactants on the promoting effect of medium chain glyceride for the rectal absorption of β-lactam antibiotics in rats and dogs, J. Pharmacobio-Dyn. 8 (1985) 653-660.
15. [15] C.J. Kreutler and W.W. Davis, Normal and promoted GI absorption of water-soluble substances III: Absorption of antibiotics from stomach and intestine of the rat, J. Pharm. Sci. 60 (1971) 1835-1838.
16. [16] S.N. Malik, D.H. Canaham and M.W. Gouda, Effect of surfactants on absorption through membranes III: Effects of dioctyl sodium sulfosuccinate and poloxalene on absorption of a poorly absorbable drug, phenolsulfonphthalein, in rats, J. Pharm. Sci. 64 (1975) 987-990.
17. [17] J. Drewe, G. Fricker, J. Vonderscher and C. Beglinger, Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether, Br. J. Pharmacol. 108 (1993) 298-303.
18. [18] K. Sakai, T. Kutsuna, T. Nishino, Y. Fujihara and N. Yata, Contribution of calcium ion sequestration by polyoxyethylated nonionic surfactants to the enhanced colonic absorption of p-aminobenzoic acid, J. Pharm. Sci. 75 (1986) 387-390.
19. [19] E.S. Swenson, W.B. Milisen and W. Curatolo, Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility, Pharm. Res. 11 (1994) 1132-1142.
20. [20] E.K. Anderberg, C. Nystrom and P. Artursson, Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells, J. Pharm. Sci. 81 (1992) 879-887.
21. [21] E.K. Anderberg and P. Artursson, Epithelial transport of drugs in cell culture. VIII: Effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells, J. Pharm. Sci. 82 (1993) 392-398.
22. [22] B.L. Oser and M. Oser, Nutritional studies on rats on diets containing high levels of partial ester emulsifiers, J. Nutr. 61 (1957) 235-252.
23. [23] O.G. Fitzhugh, A.R. Bourke, A.A. Nelson and J.P. Frawley, Chronic oral toxicities of four stearic acid emulsifiers, Toxicol. Appl. Pharmacol. 1 (1959) 315-331.
24. [24] K.J. Palin, A.J. Phillips and A. Ning, The oral absorption of cefoxitin from oil and emulsion vehicles in rats, Int. J. Pharm. 33 (1986) 99-104.
25. [25] M. Tomita, M. Shiga, M. Hayashi and S. Awazu, Enhancement of colonic drug absorption by the paracellular permeation route, Pharm. Res. 5 (1988) 341-346.
26. [26] M. Murakami, H. Yoshikawa, K. Takada and S. Muranishi, Effect of oleic acid vesicles on intestinal absorption carboxyfluorescein in rats, Pharm. Res. 3 (1986) 35-40.
27. [27] N. Muranushi, E. Mack and S.W. Kim, The effects of fatty acids and their derivatives on the intestinal absorption of insulin in rat, Drug Dev. Ind. Pharm. 19 (1993) 929-941.
28. [28] M. Tomita, T. Sawada, T. Ogawa, H. Ouchi, M. Hayashi and S. Awazu, Differences in the enhancing effects of sodium caprate on colonic and jejunal drug absorption, Pharm. Res. 9 (1992) 648-653.
29. [29] M. Tomita, M. Hayashi, T. Horie, T. Ishizawa and S. Awazu, Enhancement of colonic drug absorption by the transcellular permeation route, Pharm. Res. 5 (1988) 786-789.
30. [30] E.K. Anderberg, T. Lindmark and P. Artursson, Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route, Pharm. Res. 10 (1993) 857-864.
31. [31] M. Tomita, M. Hayashi and S. Awazu, Absorption-enchancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells, J. Pharmacol. Exp. Ther. 272 (1995) 739-743.
32. [32] T. Sawada, T. Ogawa, M. Tomita, M. Hayashi and S. Awazu, Role of paracellular pathway in nonelectrolyte permeation across rat colon epithelium enhanced by sodium caprate and sodium caprylate, Pharm. Res. 8 (1991) 1365-1371.
33. [33] H. Kajii, T. Horie, M. Hayashi and S. Awazu, Effects of sodium salicylate and caprylate as adjuvants of drug absorption on isolated rat small intestinal epithelial cells, Int. J. Pharm. 33 (1986) 253-255.
34. [34] B.S. Ramakrishna, M. Mathan and V.I. Mathan, Alteration of colonic absorption by long-chain unsaturated fatty acids, Scand. J. Gastroenterol. 29 (1994) 54-58.
35. [35] G. Beskid, J. Unowsky, C.R. Behl, J. Siebelist, J.L. Tossounian, C.M. McGarry, N.H. Shah and R. Cleeland, Enteral, oral, and rectal absorption of ceftriaxone using glyceride enhancers, Chemotherapy 34 (1988) 77-84.
36. [36] J. Unowsky, C.R. Behl, G. Beskid, J. Sattler, J. Halpern and R. Cleeland, Effect of medium chain glycerides on enteral and rectal absorption of β-lactam and aminoglycoside antibiotics, Chemotherapy 34 (1988) 272-276.
37. [37] I. Ueda, F. Shimojo and J. Kozatani, Effect of ethyl cellulose in a medium-chain triglyceride on the bioavailability of ceftizoxime, J. Pharm. Sci. 72 (1983) 454-458.
38. [38] M. Sekine, H. Terashima, K. Sasahara, K. Nishimura, R. Okada and S. Awazu, Improvement of bioavailability of poorly absorbed drugs. II. Effect of medium chain glyceride base on the intestinal absorption of cefmetazole sodium in rats and dogs, J. Pharmacobio-Dyn. 8 (1985) 286-295.
39. [39] N. Muranushi, Y. Nakajima, M. Kinugawa, S. Muranishi and H. Sezaki, Mechanism for the inducement of the intestinal absorption of poorly absorbed drugs by mixed micelles II. Effect of the incorporation of various lipids on the permeability of liposomal membranes, Int. J. Pharm. 4 (1980) 281-290.
40. [40] P.P. Constantinides, J.-P. Scalart, C. Lancaster, J. Marcello, G. Marks, H. Ellens and P.L. Smith, Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides, Pharm. Res. 11 (1994) 1385-1390.
41. [41] K. Sagara, K. Higaki, A. Yamazaki, M. Hashida and H. Sezaki, Effect of medium-chain glycerides on the membrane transport of D-glucose and sulfanilic acid in the intestinal brush-border membrane vesicles, J. Pharmacobio-Dyn. 13 (1990) 57-63.
42. [42] J. Hastewell, S. Lynch, R. Fox, I. Williamson, P. Skelton-Stroud and M. Mackay, Enhancement of human calcitonin absorption across the rat colon in vivo, Int. J. Pharm. 101 (1994) 115-120.
43. [43] L. Lohikangas, M. Wilen, M. Einarsson and P. Artursson, Effects of a new lipid-based drug delivery system on the absorption of low molecular weight heparin (Fragmin) through monolayers of human intestinal epithelial Caco-2 cells and after rectal administration to rabbits, Eur. J. Pharm. Sci. 1 (1994) 297-305.
44. [44] M. Sekine, E. Maeda, K. Sasahara, R. Okada, K. Kimura, M. Fukami and S. Awazu, Improvement of bioavailability of poorly absorbed drugs. III. Oral acute toxicity and local irritation of medium chain glyceride, J. Pharmacobio-Dyn. 8 (1985) 633-644
45. [45] J.A. Fix, K. Engle, P.A. Porter, P.S. Leppert, S.J. Selk, C.R. Gardner and J. Alexander, Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract, Am. J. Physiol. 251 (1986) G332-G340.
46. [46] S.C. Sutton, E.L. LeCluyse, L. Cammack and J.A. Fix, Enhanced bioavailability of cefoxitin using palmitoyl L-carnitine. I. Enhancer activity in different intestinal regions, Pharm. Res. 9 (1992) 191-194.
47. [47] S.C. Sutton, E.L. LeCluyse, K. Engle, J.D. Pipkin and J.A. Fix, Enhanced bioavailability of cefoxitin using palmitoylcarnitine. II. Use of directly compressed tablet formulations in the rat and dog, Pharm. Res. 10 (1993) 1516-1520.
48. [48] G.-B. Park, Z. Shao and A. Mitra, Acyclovir permeation enhancement across intestinal and nasal mucosae by bile salt-acylcarnitine mixed micelles, Pharm. Res. 9 (1992) 1262-1267
49. [49] J.H. Hochman, J.A. Fix and E.L. LeCluyse, In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine, J. Pharmacol. Exp. Ther. 269 (1994) 813-822.
50. [50] E.L. LeCluyse, L.E. Appel and S.C. Sutton, Relationship between drug absorption enhancing activity and membrane perturbing effects of acylcarnitines, Pharm. Res. 8 (1991) 84-87.
51. [51] E.L. LeCluyse, S.C. Sutton and J.A. Fix, In vitro effects of long-chain acylcarnitines on the permeability, transepithelial electrical resistance and morphology of rat colonic mucosa, J. Pharmacol. Exp. Ther. 265 (1993) 955-962.
52. [52] S.A. Mousa, J.M. Bozarth, M.S. Forsythe, S.M. Jackson, A. Leamy, M.S. Diemer, R.P. Kapil, R.M. Knabb, M.C. Mayo, S.K. Pierce, W.F. DeGrado, M.J. Thoolen and T.M. Reilly, Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist, Circulation 89 (1994) 3-12.
53. [53] B.J. Aungst and H. Saitoh, Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist, Pharm. Res. 13 (1996) 114-119.
54. [54] R.R. Wexler, D.J. Carini, J.V. Duncia, A.L. Johnson, G.J. Wells, A.T. Chiu, P.C. Wong and P.B.M.W.M. Timmermans, Rationale for the chemical development of angiotensin II receptor antagonists, Am. J. Hypertens. 5 (1992) 209S-220S.
55. [55] Y.N. Wong, K.A. Holm, D.L. Burcham, S.-M. Huang and C.Y. Quon, The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs, Biopharm. Drug Disp. 15 (1994) 53-63.